Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
Insmed Incorporated (NASDAQ:INSM) shares jumped almost 8% in early trade on Monday after the company reported positive topline results from a Phase 3b study evaluating its lung disease therapy ARIKAYCE. The ENCORE trial assessed ARIKAYCE (amikacin liposome inhalation suspension) in combination with standard multidrug therapy versus placebo plus multidrug therapy in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection who had not previously received antibiotics. The study met its primary endpoint, showing a statistically significant improvement in respiratory symptom scores at Month 13 compared with the control group. Patients receiving ARIKAYCE saw a 17.77-point improvement from baseline, compared with 14.66 points in the placebo arm, a difference of 3.11 points. All multiplicity-controlled secondary endpoints were also met, including culture conversion rates. By Month 6, 87.8% of patients in the ARIKAYCE group achieved culture conversion, compared wit
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
- Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]Yahoo! Finance
- Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.MarketBeat
- S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead [Barron's]Barrons
- Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease [Yahoo! Finance]Yahoo! Finance
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 3/23/26 - Form 8-K
- 3/20/26 - Form 4
- 3/19/26 - Form 144
- INSM's page on the SEC website